tiprankstipranks
Inventiva Gains Positive Nod for Lanifibranor Trial
Company Announcements

Inventiva Gains Positive Nod for Lanifibranor Trial

Inventiva (IVA) has released an update.

Don't Miss our Black Friday Offers:

Inventiva has announced a positive recommendation from the Data Monitoring Committee for its NATiV3 Phase 3 clinical trial of lanifibranor, highlighting the drug’s promising safety profile in treating MASH. With over 1000 patients involved, this endorsement reinforces lanifibranor as a potential breakthrough in addressing metabolic liver diseases. Investors and market analysts may view this as a significant step forward for Inventiva’s clinical and commercial prospects.

For further insights into IVA stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskInventiva Reports Voting Rights and Advances Clinical Trials
TipRanks Auto-Generated NewsdeskInventiva Prepares for Key General Meeting and Financing Plans
TipRanks Auto-Generated NewsdeskInventiva’s Phase 2 Results Boost Hope for MASH Treatment
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App